Dr. Anna Manukyan Nasse, MD

Dr. Nasse practices at Wexford Hospital in Wexford, Pennsylvania, part of Highmark Health.

Dr. Nasse's NPI, 1437577095, was assigned on April 1, 2014. Dr. Nasse holds Pennsylvania license MD461207.

Dr. Nasse's primary practice is Wexford Hospital, at 12351 Perry Highway, Wexford, PA 15090 in Allegheny County. The practice phone is (412) 295-3319.

Dr. Nasse's primary practice is Wexford Hospital in Wexford, Pennsylvania, part of Highmark Health. Dr. Nasse is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Nasse to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nasse practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Nasse's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Nasse is licensed in Pennsylvania.

CMS data shows 313 Medicare services from Dr. Nasse across 5 procedure codes in 2024, for 153 Medicare patients. Medicare paid $23,634 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 153 Medicare patients who saw Dr. Nasse in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have arthritis, and 75% have high blood pressure. 23% are also on Medicaid. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nasse's median patient age at 73, with 52% women.

In 2024, Dr. Nasse wrote 148 Medicare Part D claims for 73 patients. 86% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $53 in total drug cost. In 2018, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Nasse for performance year 2024, reported as part of a group. Dr. Nasse accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 16 general payments to Dr. Nasse from 5 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $212.